Antibody therapy shields vulnerable patients from severe COVID-19
NCT ID NCT05439044
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracked over 4,200 immunocompromised patients who received monoclonal antibodies to prevent or treat severe COVID-19. Researchers measured how many were hospitalized or died from the virus. The goal was to see if these antibody treatments help protect people whose immune systems don't respond well to vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOCOMPROMISED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital
Paris, Île-de-France Region, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may forecast survival in intensive care patients
- Could a simple swab replace a lung scope for pneumocystis diagnosis?
- New immune score aims to predict infections in transplant patients
- Scientists probe nose immunity in vulnerable patients
- Shingles vaccine put to the test in frail patients
- New study to see if antivirals help immunocompromised COVID patients